Melflufen for the treatment of multiple myeloma - Nantes Université
Article Dans Une Revue Expert Review of Clinical Pharmacology Année : 2022

Melflufen for the treatment of multiple myeloma

Résumé

Melphalan flufenamide (melflufen) is a first-in-class peptide-drug conjugate that takes advantage of increased aminopeptidase activity inside tumor cells to rapidly release alkylating agents therein. Melflufen in combination with dexamethasone has been evaluated in multiple clinical trials in patients with relapsed/refractory multiple myeloma (MM).
Fichier non déposé

Dates et versions

hal-04759644 , version 1 (30-10-2024)

Identifiants

Citer

Enrique Ocio, Omar Nadeem, Fredrik Schjesvold, Francesca Gay, Cyrille Touzeau, et al.. Melflufen for the treatment of multiple myeloma. Expert Review of Clinical Pharmacology, 2022, 15 (4), pp.371-382. ⟨10.1080/17512433.2022.2075847⟩. ⟨hal-04759644⟩
0 Consultations
0 Téléchargements

Altmetric

Partager

More